Search

Your search keyword '"Pilar de Lucas-Ramos"' showing total 14 results
Start Over Author "Pilar de Lucas-Ramos" Topic medicine.medical_specialty
14 results on '"Pilar de Lucas-Ramos"'

1. The importance of symptoms in the longitudinal variability of clusters in COPD patients: A validation study

Author

Jose M. Marin, Juan Pablo Torres, Ciro Casanova, Borja G. Cosío, Cristina Martínez-González, and Pilar de Lucas-Ramos

Subjects
Pulmonary and Respiratory Medicine, Spirometry, Pediatrics, medicine.medical_specialty, COPD, Validation study, medicine.diagnostic_test, business.industry, Genetic heterogeneity, Copd patients, medicine.disease, respiratory tract diseases, 03 medical and health sciences, 0302 clinical medicine, 030228 respiratory system, Quality of life, medicine, 030212 general & internal medicine, business, Airway, Body mass index
Abstract

Background and objective Cluster analysis has been utilized to explore phenotypic heterogeneity in chronic obstructive pulmonary disease (COPD). To date, little is known about the longitudinal variability of clusters in COPD patients. We aimed to evaluate the 2-year cluster variability in stable COPD patients. Methods We evaluated the following variables in COPD patients at baseline and 2 years later: age, gender, pack-year history, body mass index (BMI), modified Medical Research Council (MMRC) scale, 6-min walking distance (6MWD), spirometry and COPD Assessment Test (CAT). Patient classification was performed using cluster analysis at baseline and 2 years later. Each patient’s cluster variability after 2 years and its parameters associated with cluster change were explored. Results A total of 521 smokers with COPD were evaluated at baseline and 2 years later. Three different clusters were consistently identified at both evaluation times: cluster A (of younger age, mild airway limitation, few symptoms), cluster B (intermediate) and cluster C (of older age, severe airway limitation and highly symptomatic). Two years later, 70% of patients were unchanged, whereas 30% changed from one cluster to another: 20% from A to B; 15% from B to A; 15% from B to C; 42% from C to B and 8% from C to A. 6MWD, forced expiratory volume in 1 s (FEV1) % and CAT were the principal parameters responsible for this change. Conclusion After 2 years of follow-up, most of the COPD patients maintained their cluster assignment. Exercise tolerance, lung function and quality of life were the main driving parameters in those who change their cluster assignment.

Published
2017
Full Text
View/download PDF

2. Differential Effect of Modified Medical Research Council Dyspnea, COPD Assessment Test, and Clinical COPD Questionnaire for Symptoms Evaluation Within the New GOLD Staging and Mortality in COPD

Author

José Luis López-Campos, Jose M. Marin, Miryam Calle-Rubio, Nuria Feu-Collado, Rafael Golpe, Germán Peces-Barba, Carlos Javier Gutiérrez Cabrera, Borja G. Cosío, Eva Balcells, Cristina Martínez-González, Ingrid Solanes-García, Alicia Marin, Celia Lacarcel, Alfredo de Diego-Damia, Juan P. de-Torres, Isabel Mir-Viladrich, Ramón Agüero, Rosa Irigaray, Margarita Marín, Pilar de Lucas-Ramos, Antonia Llunell, Juan José Soler-Cataluña, Juan B. Galdiz, Joan B. Soriano, Ciro Casanova, and Inmaculada Alfageme

Subjects
Male, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Critical Care and Intensive Care Medicine, Cohort Studies, Pulmonary Disease, Chronic Obstructive, Predictive Value of Tests, Forced Expiratory Volume, Surveys and Questionnaires, Internal medicine, medicine, Health Status Indicators, Humans, Aged, COPD, Receiver operating characteristic, business.industry, Middle Aged, Prognosis, medicine.disease, Obstructive lung disease, respiratory tract diseases, Dyspnea, ROC Curve, Spain, Predictive value of tests, Cohort, Physical therapy, Copd assessment test, Female, Observational study, Symptom Assessment, Cardiology and Cardiovascular Medicine, business, Cohort study
Abstract

OBJECTIVE: The modified Medical Research Council (mMRC) dyspnea, the COPD Assessment Test (CAT), and the Clinical COPD Questionnaire (CCQ) have been interchangeably proposed by GOLD (Global Initiative for Chronic Obstructive Lung Disease) for assessing symptoms in patients with COPD. However, there are no data on the prognostic value of these tools in terms of mortality. We endeavored to evaluate the prognostic value of the CAT and CCQ scores and compare them with mMRC dyspnea. METHODS: We analyzed the ability of these tests to predict mortality in an observational cohort of 768 patients with COPD (82% men; FEV1, 60%) from the COPD History Assessment in Spain (CHAIN) study, a multicenter observational Spanish cohort, who were monitored annually for a mean follow-up time of 38 months. RESULTS: Subjects who died (n = 73; 9.5%) had higher CAT (14 vs 11, P = .022), CCQ (1.6 vs 1.3, P = .033), and mMRC dyspnea scores (2 vs 1, P < .001) than survivors. Receiver operating characteristic analysis showed that higher CAT, CCQ, and mMRC dyspnea scores were associated with higher mortality (area under the curve: 0.589, 0.588, and 0.649, respectively). CAT scores >= 17 and CCQ scores >2.5 provided a similar sensitivity than mMRC dyspnea scores >= 2 to predict all-cause mortality. CONCLUSIONS: The CAT and the CCQ have similar ability for predicting all-cause mortality in patients with COPD, but were inferior to mMRC dyspnea scores. We suggest new thresholds for CAT and CCQ scores based on mortality risk that could be useful for the new GOLD grading classification.

Published
2015
Full Text
View/download PDF

3. Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD

Author

Ramón Agüero, Eva Balcells, Pilar de Lucas-Ramos, Celia Lacarcel, Inmaculada Alfageme, Jose M. Marin, Carlos Javier Gutiérrez Cabrera, Victor Pinto-Plata, Miguel Divo, Juan P. de-Torres, Alfredo de Diego, Rafael Golpe, Myriam Calle-Rubio, Amalia Moreno, Ingrid Solanes, Juan B. Galdiz, José Luis López-Campos, Joan B. Soriano, Nuria Feu-Collado, Bartolome R. Celli, Juan José Soler-Cataluña, Antonia Fuster, Amparo Romero, Antonia Llunell, Borja G. Cosío, Cristina Martínez-González, Ciro Casanova, Margarita Marín, Germán Peces-Barba, [Casanova, Ciro] Hosp Univ Ntra Sra La Candelaria, Pulmonol Dept, Tenerife, Spain, [Celli, Bartolome R.] Brigham & Womens Hosp, Pulm & Crit Care Dept, 75 Francis St, Boston, MA 02115 USA, [Divo, Miguel] Brigham & Womens Hosp, Pulm & Crit Care Dept, 75 Francis St, Boston, MA 02115 USA, [de-Torres, Juan P.] Clin Univ Navarra, Pulm Dept, Pamplona, Spain, [Martinez-Gonzalez, Cristina] Hosp Cent Asturias, Pulm Dept, Oviedo, Spain, [Cosio, Borja G.] Hosp Son Espases IdISPa, Pulm Dept, Palma de Mallorca, Spain, [Cosio, Borja G.] Inst Salud Carlos III, CIBER Enfermedades Resp CIBERES, Madrid, Spain, [Peces-Barba, German] Inst Salud Carlos III, CIBER Enfermedades Resp CIBERES, Madrid, Spain, [Luis Lopez-Campos, Jose] Inst Salud Carlos III, CIBER Enfermedades Resp CIBERES, Madrid, Spain, [Pinto-Plata, Victor] Baystate Med Ctr, Springfield, MA USA, [de Lucas-Ramos, Pilar] Hosp Gregorio Maranon, Pulm Dept 1, Madrid, Spain, [Fuster, Antonia] Hosp Son Llatzer, Pulm Dept, Mallorca, Spain, [Peces-Barba, German] Fdn Jimenez Diaz, Pulm Dept, Madrid, Spain, [Calle-Rubio, Myriam] Univ Complutense Madrid, Fac Med, Med Dept, Hosp Clin San Carlos,Pulm Dept, Madrid, Spain, [Solanes, Ingrid] Univ Autonoma Barcelona, Hosp Santa Creu & Sant Pau, Pulm Dept, Barcelona, Spain, [Aguero, Ramon] Hosp Marques Valdecilla, Pulm Dept, Santander, Spain, [Feu-Collado, Nuria] Hosp Univ Reina Sofia, IMIBIC, UCO, Pulm Dept, Cordoba, Spain, [Alfageme, Inmaculada] Hosp Univ Valme, Pulm Dept, Seville, Spain, [De Diego, Alfredo] Hosp Univ La Fe, Pulm Dept, Valencia, Spain, [Romero, Amparo] Hosp Manacor, Pulm Dept, Mallorca, Spain, [Balcells, Eva] Hosp Mar, Pulm Dept, Barcelona, Spain, [Llunell, Antonia] Hosp Tarrasa, Pulm Dept, Tarrasa, Spain, [Galdiz, Juan B.] Hosp Cruces, Pulm Dept, Bilbao, Spain, [Marin, Margarita] Hosp Gen Castellon, Pulm Dept, Castellon de La Plana, Spain, [Moreno, Amalia] Hosp Parc Tauli, Pulm Dept, Barcelona, Spain, [Cabrera, Carlos] Hosp Dr Negrin, Pulm Dept, Las Palmas Gran Canaria, Spain, [Golpe, Rafael] Hosp Univ Lucus Augusti, Pulm Dept, Lugo, Spain, [Lacarcel, Celia] Hosp Ciudad Jaen, Pulm Dept, Jaen, Spain, [Soriano, Joan B.] Hosp Univ La Princesa IISP, Inst Invest, Madrid, Spain, [Luis Lopez-Campos, Jose] Hosp Univ Virgen Rocio, Inst Biomed Sevilla IBiS, Unidad Med Quirrurg Enfermedades Resp, Seville, Spain, [Soler-Cataluna, Juan J.] Hosp Arnau Vilanova, Pulm Dept, Valencia, Spain, [Marin, Jose M.] Hosp Univ Miguel Servet, IISAragon, CIBERES, Pulm Dept, Zaragoza, Spain, and AstraZeneca (Madrid, Spain)

Subjects
Male, Cohort Studies, Leukocyte Count, Pulmonary Disease, Chronic Obstructive, 0302 clinical medicine, Risk Factors, Forced Expiratory Volume, Prevalence, Medicine, Eosinophilia, 030212 general & internal medicine, Obstructive pulmonary-disease, COPD, Inhaled corticosteroids, respiratory system, Middle Aged, medicine.anatomical_structure, Cohort, Disease Progression, Female, medicine.symptom, Cohort study, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Efficacy, Guidelines, Exacerbations, 03 medical and health sciences, Internal medicine, Humans, In patient, Risk factor, Survival analysis, Aged, Clinical characteristics, business.industry, Biomarker, Eosinophil, medicine.disease, Survival Analysis, Asthma, respiratory tract diseases, Eosinophils, Dyspnea, 030228 respiratory system, Spain, Immunology, Fluticasone, business
Abstract

The impact of blood eosinophilia in chronic obstructive pulmonary disease (COPD) remains controversial.To evaluate the prevalence and stability of a high level of blood eosinophils (>= 300 cells.mu L-1) and its relationship to outcomes, we determined blood eosinophils at baseline and over 2 years in 424 COPD patients (forced expiratory volume in 1 s (FEV1) 60% predicted) and 67 smokers without COPD from the CHAIN cohort, and in 308 COPD patients (FEV1 60% predicted) in the BODE cohort. We related eosinophil levels to exacerbations and survival using Cox hazard analysis.In COPD patients, 15.8% in the CHAIN cohort and 12.3% in the BODE cohort had persistently elevated blood eosinophils at all three visits. A significant proportion (43.8%) of patients had counts that oscillated above and below the cut-off points, while the rest had persistent eosinophil levels = 300 cells.mu L-1) and its relationship to outcomes, we determined blood eosinophils at baseline and over 2 years in 424 COPD patients (forced expiratory volume in 1 s (FEV1) 60% predicted) and 67 smokers without COPD from the CHAIN cohort, and in 308 COPD patients (FEV1 60% predicted) in the BODE cohort. We related eosinophil levels to exacerbations and survival using Cox hazard analysis.In COPD patients, 15.8% in the CHAIN cohort and 12.3% in the BODE cohort had persistently elevated blood eosinophils at all three visits. A significant proportion (43.8%) of patients had counts that oscillated above and below the cut-off points, while the rest had persistent eosinophil levels = 300 cells.mu L-1 persisting over 2 years was not a risk factor for COPD exacerbations. High eosinophil count was associated with better survival.

Published
2017

4. Clinical Application of the COPD Assessment Test

Author

Eva Balcells, Juan José Soler-Cataluña, Pilar de Lucas-Ramos, Ciro Casanova, Ramón Agüero Balbin, Joan B. Soriano, Miryam Calle-Rubio, José Luis López-Campos, Ingrid Solanes-García, Juan Bautista Galdiz Iturri, Antonia Llunell Casanovas, Germán Peces-Barba, Inmaculada Alfageme Michavila, Nuria Feu-Collado, Rosa Irigaray, Margarita Marín Royo, Isabel Mir-Viladrich, Cristina Martínez-González, Alfredo de Diego-Damia, Juan P. de Torres, Borja G. Cosío, and Jose M. Marin

Subjects
Pulmonary and Respiratory Medicine, BODE index, COPD, medicine.medical_specialty, business.industry, Critical Care and Intensive Care Medicine, Hospital Anxiety and Depression Scale, medicine.disease, respiratory tract diseases, Interquartile range, Severity of illness, Cohort, Physical therapy, Medicine, Cardiology and Cardiovascular Medicine, business, Prospective cohort study, Cohort study
Abstract

OBJECTIVE The COPD Assessment Test (CAT) has been proposed for assessing health status in COPD, but little is known about its longitudinal changes. The objective of this study was to evaluate 1-year CAT variability in patients with stable COPD and to relate its variations to changes in other disease markers. METHODS We evaluated the following variables in smokers with and without COPD at baseline and after 1 year: CAT score, age, sex, smoking status, pack-year history, BMI, modified Medical Research Council (mMRC) scale, 6-min walk distance (6MWD), lung function, BODE (BMI, obstruction, dyspnea, exercise capacity) index, hospital admissions, Hospital and Depression Scale, and the Charlson comorbidity index. In patients with COPD, we explored the association of CAT scores and 1-year changes in the studied parameters. RESULTS A total of 824 smokers with COPD and 126 without COPD were evaluated at baseline and 441 smokers with COPD and 66 without COPD 1 year later. At 1 year, CAT scores for patients with COPD were similar (± 4 points) in 56%, higher in 27%, and lower in 17%. Of note, mMRC scale scores were similar (± 1 point) in 46% of patients, worse in 36%, and better in 18% at 1 year. One-year CAT changes were best predicted by changes in mMRC scale scores (β-coefficient, 0.47; P CONCLUSIONS One-year longitudinal data show variability in CAT scores among patients with stable COPD similar to mMRC scale score, which is the best predictor of 1-year CAT changes. Further longitudinal studies should confirm long-term CAT variability and its clinical applicability. TRIAL REGISTRY ClinicalTrials.gov; No.: NCT01122758; URL: www.clinicaltrials.gov

Published
2014
Full Text
View/download PDF

5. Redefining Cut-Points for High Symptom Burden of the Global Initiative for Chronic Obstructive Lung Disease Classification in 18,577 Patients With Chronic Obstructive Pulmonary Disease

Author

Masanori Yoshikawa, Daisy J.A. Janssen, Selina Dürr, Rudolf Joerres, Julia Billington, Nicholas Locantore, Florin Mihaltan, Sally Singh, Dimitar Sajkov, Thys van der Molen, Borja G. Cosío, Guilherme F. da Silva, Sarah Houben-Wilke, Ian Norman, Baykal Tulek, Jose M. Marin, David Miedinger, Samantha Coster, Janwillem W. H. Kocks, Sang Do Lee, Karel Hejduk, Juan P. de Torres, Maria Gonik, Mark Small, Samantha S.C. Kon, Nobuyuki Horita, Katherine A. Webb, Naseh Sigari, Ioanna Tsiligianni, Natya Raghavan, Yoshitaka Ogata, William D.-C. Man, Afroditi K. Boutou, Cristina Martínez, Marc Miravitlles, Lowie E.G.W. Vanfleteren, Miriam T.J. Groenen, Barbora Novotna, Isabel Mir, Miguel Guimaraes, Alvar Agusti, Nart Bedin Atalay, Dionne E. Smid, Trevor Murrells, Stefanie Brighenti-Zogg, Henrik Watz, Seigo Minami, José Luis López-Campos, Frits M.E. Franssen, Nicholas S Hopkinson, Pilar de Lucas-Ramos, Emiel F.M. Wouters, James Piercy, Melissa Jehn, Emma Chaplin, Vladimir Koblizek, Ciro Casanova, Nikolaos Tzanakis, Rebecca Tanner, Hiroshi Kimura, Lana Maricic, Nienke Nakken, David Price, Alberto Fernández-Villar, Denis E. O'Donnell, Annika Karch, Martijn A. Spruit, Yu-Il Kim, Joan B. Soriano, Ines Ladeira, Yu Nishijima, Namhee Kwon, Victoria Higgins, Laura Mendoza, Eanes Delgado Barros Pereira, Julia L. Kelly, Thomas Ringbaek, Guogang G. Xie, Chaicharn Pothirat, James W. Dodd, Joerg D. Leuppi, RS: NUTRIM - R3 - Respiratory & Age-related Health, Pulmonologie, Afdeling Onderwijs FHML, RS: NUTRIM - R3 - Chronic inflammatory disease and wasting, Promovendi NTM, MUMC+: MA Longziekten (3), [Smid, Dionne E.] CIRO, Dept Res & Educ, Hornerheide 1, NL-6085 NM Horn, Netherlands, [Franssen, Frits M. E.] CIRO, Dept Res & Educ, Hornerheide 1, NL-6085 NM Horn, Netherlands, [Groenen, Miriam T. J.] CIRO, Dept Res & Educ, Hornerheide 1, NL-6085 NM Horn, Netherlands, [Houben-Wilke, Sarah] CIRO, Dept Res & Educ, Hornerheide 1, NL-6085 NM Horn, Netherlands, [Janssen, Daisy J. A.] CIRO, Dept Res & Educ, Hornerheide 1, NL-6085 NM Horn, Netherlands, [Nakken, Nienke] CIRO, Dept Res & Educ, Hornerheide 1, NL-6085 NM Horn, Netherlands, [Vanfleteren, Lowie E. G. W.] CIRO, Dept Res & Educ, Hornerheide 1, NL-6085 NM Horn, Netherlands, [Wouters, Emiel F. M.] CIRO, Dept Res & Educ, Hornerheide 1, NL-6085 NM Horn, Netherlands, [Spruit, Martijn A.] CIRO, Dept Res & Educ, Hornerheide 1, NL-6085 NM Horn, Netherlands, [Franssen, Frits M. E.] Maastricht Univ, Med Ctr, Dept Resp Med, Maastricht, Netherlands, [Vanfleteren, Lowie E. G. W.] Maastricht Univ, Med Ctr, Dept Resp Med, Maastricht, Netherlands, [Wouters, Emiel F. M.] Maastricht Univ, Med Ctr, Dept Resp Med, Maastricht, Netherlands, [Gonik, Maria] Biomax Informat AG, Planegg, Germany, [Miravitlles, Marc] Hosp Univ Hebron, CIBER Enfermedades Resp CIBERES, Pneumol Dept Hosp, Barcelona, Spain, [Casanova, Ciro] Hosp Univ NS Candelaria, Pulmonaty Dept, Santa Cruz de Tenerife, Spain, [Casanova, Ciro] Hosp Univ NS Candelaria, Res Unit, Santa Cruz de Tenerife, Spain, [Cosio, Borja G.] Hosp Son Espases IdISPa CIBERES, Dept Resp Med, Islas Baleares, Spain, [de Lucas-Ramos, Pilar] Hosp Gen Univ Gregorio Maranon, Pulm Dept, Madrid, Spain, [Marin, Jose M.] Hosp Univ Miguel Servet, IISAragon, CIBER Enfermedades Resp, Zaragoza, Spain, [Martinez, Cristina] Hosp Univ Cent Asturias, Inst Nacl Silicosis, Pneumol Serv, Oviedo, Spain, [Mir, Isabel] Hosp Gen Univ Gregorio Maranon, Pulm Dept, Madrid, Spain, [Soriano, Joan B.] Univ Autonoma Madrid, Hosp Univ Princesa, Inst Invest, IISP, Madrid, Spain, [de Torres, Juan P.] Clin Univ Navarra, Pulm Dept, Pamplona, Spain, [Agusti, Alvar] Univ Barcelona, Hosp Clin, Resp Inst, Barcelona, Spain, [Agusti, Alvar] CIBERES, Madrid, Spain, [Atalay, Nart B.] TOBB Univ Econ & Technol, Dept Psychol, Ankara, Turkey, [Billington, Julia] Surbiton Hlth Ctr, Cent Surg, Surrey, England, [Boutou, Afroditi K.] G Gennimats Gen Hosp, Intens Care Unit, Thessaloniki, Greece, [Boutou, Afroditi K.] Aristotle Univ Thessaloniki, Resp Failure Unit, Thessaloniki, Greece, [Brighenti-Zogg, Stefanie] Univ Clin Med, Cantonal Hosp Baselland, Liestal, Switzerland, [Durr, Selina] Univ Clin Med, Cantonal Hosp Baselland, Liestal, Switzerland, [Leuppi, Joerg D.] Univ Clin Med, Cantonal Hosp Baselland, Liestal, Switzerland, [Miedinger, David] Univ Clin Med, Cantonal Hosp Baselland, Liestal, Switzerland, [Chaplin, Emma] Univ Hosp Leicester NHS Trust, NIHR Leicester Resp Biomed Res Unit, Ctr Exercise & Rehabil Sci, Leicester, Leics, England, [Singh, Sally] Univ Hosp Leicester NHS Trust, NIHR Leicester Resp Biomed Res Unit, Ctr Exercise & Rehabil Sci, Leicester, Leics, England, [Coster, Samantha] Kings Coll London, Florence Nightingale Fac Nursing & Midwifery, London, England, [Murrells, Trevor J.] Kings Coll London, Florence Nightingale Fac Nursing & Midwifery, London, England, [Norman, Ian J.] Kings Coll London, Florence Nightingale Fac Nursing & Midwifery, London, England, [Dodd, James W.] Univ Bristol, Southmead Hosp Bristol, North Bristol Lung Ctr, Acad Resp Unit, Bristol, Avon, England, [Fernandez-Villar, Alberto] Complexo Hosp Vigo, Inst Invest Biomed Vigo, Serv Neumol, Pontevedra, Spain, [Guimaraes, Miguel] Ctr Hosp Vila Nova Gaia Espinho, Pulmonol Dept, Vila Nova De Gaia, Portugal, [Ladeira, Ines] Ctr Hosp Vila Nova Gaia Espinho, Pulmonol Dept, Vila Nova De Gaia, Portugal, [Hejduk, Karel] Masaryk Univ, Fac Med, Inst Biostat & Analyses, Brno, Czech Republic, [Higgins, Victoria] Adelphi Real World, Bollington, England, [Piercy, James] Adelphi Real World, Bollington, England, [Small, Mark] Adelphi Real World, Bollington, England, [Hopkinson, Nicholas S.] Imperial Coll London, Royal Brompton & Harefield NHS Fdn Trust, NIHR Resp Biomed Res Unit, London, England, [Tanner, Rebecca J.] Imperial Coll London, Royal Brompton & Harefield NHS Fdn Trust, NIHR Resp Biomed Res Unit, London, England, [Horita, Nobuyuki] Yokohama City Univ, Grad Sch Med, Dept Pulmonol, Yokohama, Kanagawa, Japan, [Jehn, Melissa] Charite Univ Med Berlin, Arbeitsbereich Ambulante Pneumol, Berlin, Germany, [Joerres, Rudolf] Inst & Output Clin Occupat & Environm Med, Munich, Germany, [Karch, Annika] Hannover Med Sch, Inst Biostat, Hannover, Germany, [Kelly, Julia L.] Imperial Coll London, NIHR Resp Dis Biomed Res Unit Royal Brompton, Natl Heart & Lung Inst, Acad Unit Sleep & Ventilat, London, England, [Kelly, Julia L.] Harefield NHS Fdn Trust & Imperial Coll, London, England, [Kim, Yu-Il] Chonnam Natl Univ Hosp, Dept Internal Med, Div Pulmonol, Donggu, Gwangju, South Korea, [Kimura, Hiroshi] Nara Med Univ, Dept Internal Med 2, Nara, Japan, [Yoshikawa, Masanori] Nara Med Univ, Dept Internal Med 2, Nara, Japan, [Koblizek, Vladimir] Charles Univ Prague, Fac Med Hradec Kralove, Dept Pneumol, Hradec Kralove, Czech Republic, [Novotna, Barbora] Charles Univ Prague, Fac Med Hradec Kralove, Dept Pneumol, Hradec Kralove, Czech Republic, [Koblizek, Vladimir] Univ Hosp Hradec Kralove, Hradec Kralove, Czech Republic, [Novotna, Barbora] Univ Hosp Hradec Kralove, Hradec Kralove, Czech Republic, [Kocks, Janwillem H.] Univ Groningen, Univ Med Ctr Groningen, Groningen Res Inst Asthma, Dept Primary Care, Groningen, Netherlands, [van der Molen, Thys] Univ Groningen, Univ Med Ctr Groningen, Groningen Res Inst Asthma, Dept Primary Care, Groningen, Netherlands, [Tsiligianni, Ioanna G.] Univ Groningen, Univ Med Ctr Groningen, Groningen Res Inst Asthma, Dept Primary Care, Groningen, Netherlands, [Kocks, Janwillem H.] Univ Groningen, Univ Med Ctr Groningen, GRIAC, COPD, Groningen, Netherlands, [van der Molen, Thys] Univ Groningen, Univ Med Ctr Groningen, GRIAC, COPD, Groningen, Netherlands, [Tsiligianni, Ioanna G.] Univ Groningen, Univ Med Ctr Groningen, GRIAC, COPD, Groningen, Netherlands, [Kon, Samantha S. C.] Hillingdon Hosp NHS Fdn Trust, Uxbridge, Middx, England, [Kon, Samantha S. C.] Royal Brompton & Harefield NHS Fdn Trust, NIHR Resp Biomed Res Unit, London, England, [Man, William D-C] Royal Brompton & Harefield NHS Fdn Trust, NIHR Resp Biomed Res Unit, London, England, [Kon, Samantha S. C.] Imperial Coll, London, England, [Man, William D-C] Imperial Coll, London, England, [Kwon, Namhee] GlaxoSmithICline GSK, Resp Franchise Med, London, England, [Lee, Sang-Do] Univ Ulsan, Coll Med, Clin Res Ctr Chron Obstruct Airway Dis, Asan Med Ctr,Dept Pulm & Critical Care Med, Seoul, South Korea, [Locantore, Nicholas] GlaxoSmithICline, King Of Prussia, PA USA, [Lopez-Campos, Jose L.] Univ Seville, Hosp Univ Virgen Rocio, Inst Biomed Sevilla, Unidad MedQuirarg Enfermedades Resp, Seville, Spain, [Lopez-Campos, Jose L.] Inst Salud Carlos III, CIBERES, CIBER Enfermedades Resp, Madrid, Spain, [Maricic, Lana] Univ JJ Strossmayer Osijek, Fac Med, Dept Internal Med, Univ Hosp Osijek, Osijek, Croatia, [Mendoza, Laura] Hosp Clin Univ Chile, Independencia, Region Metropol, Chile, [Mihaltan, Florin] Inst Pneumol Marius Nasta, Bucharest, Romania, [Minami, Seigo] Osaka Police Hosp, Dept Resp Med, Osaka, Japan, [Nishijima, Yu] Osaka Police Hosp, Dept Resp Med, Osaka, Japan, [Ogata, Yoshitaka] Osaka Police Hosp, Dept Resp Med, Osaka, Japan, [Nishijima, Yu] Osaka Univ, Grad Sch Med, Dept Resp Med Allergy & Rheumat Dis, Suita, Osaka, Japan, [O'Donnell, Denis E.] Queens Univ & Kingston Gen Hosp, Dept Med, Kingston, ON, Canada, [Webb, Katherine A.] Queens Univ & Kingston Gen Hosp, Dept Med, Kingston, ON, Canada, [Pereira, Eanes D.] Fed Univ Ceara Brazil, Fortaleza, Ceara, Brazil, [Price, David] Observat & Pragmat Res Inst, Singapore, Singapore, [Price, David] Univ Aberdeen, Aberdeen, Scotland, [Pothirat, Chaicharn] Chiang Mai Univ, Fac Med, Dept Internal Med, Div Pulm Crit Care & Allergy, Chiang Mai, Thailand, [Raghavan, Natya] McMaster Univ, Dept Med, Hamilton, ON, Canada, [Ringbaek, Thomas] Univ Copenhagen, Hvidovre Hosp, Dept Resp Med, Copenhagen, Denmark, [Sajkov, Dimitar] Flinders Med Ctr, Australian Resp & Sleep Med Inst, Adelaide, SA, Australia, [Sigari, Naseh] Kurdistan Univ Med Sci, Med Fac, Internal Med Dept, Sanandaj, Iran, [da Silva, Guilherme F.] Univ Fortaleza, UNIFOR, Fortaleza, Ceara, Brazil, [Tsiligianni, Ioanna G.] Agia Barbara Hlth Care Ctr, Iraklion, Greece, [Tulek, Baykal] Selcuk Univ, Fac Med, Dept Chest Dis, Konya, Turkey, [Tulek, Baykal] Univ Crete, Med Sch, Univ Hosp Herakl, Dept Thorac Med, Iraklion, Greece, [Watz, Henrik] German Ctr Lung Res, Pulm Res Inst, Lung Clin Grosshansdorf, Grosshansdorf, Germany, [Xie, Guogang G.] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Resp Med, Shanghai, Peoples R China, [Spruit, Martijn A.] Hasselt Univ, Fac Med & Life Sci, Biomed Res Inst, REVAL,Rehabil Res Ctr,BIOMED, Diepenbeek, Belgium, [Spruit, Martijn A.] Maastricht Univ, Med Ctr, NUTRIM Sch Nutr & Translat Res Metab, Dept Resp Med, Maastricht, Netherlands, MRC, National Institute for Health Research, Medical Research Council, Department of Health, Medical Research Council (MRC), EU/IMI Joint Undertaking, TOBB ETU, Faculty of Science and Literature, Department of Psychology, TOBB ETÜ, Fen Edebiyat Fakültesi, Psikoloji Bölümü, Atalay, Nart Bedin, and Groningen Research Institute for Asthma and COPD (GRIAC)

Subjects
ASSESSMENT TEST SCORE, Male, clinical significance, health status, HISTORY ASSESSMENT, Global Health, Severity of Illness Index, Pulmonary Disease, Chronic Obstructive, 0302 clinical medicine, Assessment test score, Quality of life, CLINICAL CHARACTERISTICS, QUALITY-OF-LIFE, Sickness Impact Profile, 030212 general & internal medicine, Prospective cohort study, Copd assessment test, General Nursing, POPULATION, COPD, education.field_of_study, HEALTH-STATUS, COPD ASSESSMENT TEST, Evidence-Based Medicine, medicine.diagnostic_test, Health Policy, Age Factors, Cat, CAT, General Medicine, Middle Aged, Obstructive lung disease, Health-status, 3. Good health, 1117 Public Health And Health Services, Practice Guidelines as Topic, Disease Progression, Female, Symptom Assessment, Research-council scale, Spirometry, medicine.medical_specialty, Population, Risk Assessment, 03 medical and health sciences, Sex Factors, Internal medicine, Severity of illness, medicine, Humans, GOLD, education, Aged, Receiver operating characteristic, Clinical characteristics, business.industry, 1103 Clinical Sciences, medicine.disease, RESEARCH-COUNCIL SCALE, History assessment, PHYSICAL-ACTIVITY, 030228 respiratory system, Geriatrics, Physical therapy, Physical-activity, Quality-of-life, Geriatrics and Gerontology, business
Abstract

Background: Patients with chronic obstructive pulmonary disease (COPD) can be classified into groups A/C or B/D based on symptom intensity. Different threshold values for symptom questionnaires can result in misclassification and, in turn, different treatment recommendations. The primary aim was to find the best fitting cut-points for Global initiative for chronic Obstructive Lung Disease (GOLD) symptom measures, with an modified Medical Research Council dyspnea grade of 2 or higher as point of reference.Methods: After a computerized search, data from 41 cohorts and whose authors agreed to provide data were pooled. COPD studies were eligible for analyses if they included, at least age, sex, post-bronchodilator spirometry, modified Medical Research Council, and COPD Assessment Test (CAT) total scores.Main outcomes: Receiver operating characteristic curves and the Youden index were used to determine the best calibration threshold for CAT, COPD Clinical Questionnaire, and St. Georges Respiratory Questionnaire total scores. Following, GOLD A/B/C/D frequencies were calculated based on current cut-points and the newly derived cut-points.Findings: A total of 18,577 patients with COPD [72.0% male; mean age: 66.3 years (standard deviation 9.6)] were analyzed. Most patients had a moderate or severe degree of airflow limitation (GOLD spirometric grade 1, 10.9%; grade 2, 46.6%; grade 3, 32.4%; and grade 4, 10.3%). The best calibration threshold for CAT total score was 18 points, for COPD Clinical Questionnaire total score 1.9 points, and for St. Georges Respiratory Questionnaire total score 46.0 points.Conclusions: The application of these new cut-points would reclassify about one-third of the patients with COPD and, thus, would impact on individual disease management. Further validation in prospective studies of these new values are needed. (C) 2017 AMDA - The Society for Post-Acute and Long-Term Care Medicine.

Published
2017

6. Study of Prevalence and Attitudes on Smoking in Patients on Continuous Home Oxygen Therapy. Toma Study

Author

Juan Luis Rodríguez Hermosa, Carlos A. Jiménez-Ruiz, Inmaculada Ramos García, Enrique Zamora García, Segismundo Solano Reina, Concepción Losada Molina, Pilar de Lucas Ramos, Ali Droghan, Antonio Martínez Verdasco, Salvador Díaz Lobato, Teresa García Carmona, Javier de la Cruz Labrado, and José Miguel Rodríguez González-Moro

Subjects
Male, medicine.medical_specialty, Cross-sectional study, Subject group, Home oxygen therapy, Population, Nicotine, Internal medicine, Prevalence, medicine, Humans, In patient, education, Aged, education.field_of_study, business.industry, Smoking, Oxygen Inhalation Therapy, Mean age, General Medicine, Home Care Services, Confidence interval, Cross-Sectional Studies, Physical therapy, Female, business, Attitude to Health, medicine.drug
Abstract

The objective of this study is to analyse the prevalence, attitudes and characteristics of smoking in the population of patients subjected to Long Term Domiciliary Oxygen Therapy (LTDOT) in the Community of Madrid.A representative sample of 845 subjects (of which 461 (46%) were male) was obtained from a total of 11,174 who fulfilled the inclusion criteria. The mean age was 78.25 years (95% Confidence Interval (CI): 77.55-78.95; SD=10.36). A descriptive cross-sectional study was conducted based on questionnaires as well as cooximetry.Forty-eight subjects (5.7%; 95%CI: 4.3%-7.5%) were smokers and 438 (51.8%; 95%CI: 48.5%-55.2%) were ex-smokers. The percentage of active smokers was higher in the 60 years or less subject group (χ(2); P0.001). The large majority (75%) of smokers were men, their proportion being significantly higher than that of current non-smokers (χ(2); P0.003). The mean score in the Fagerström Test was 3.6. More than 65% of smokers had their first cigarette up to 30 min from getting up in the morning, and 45% of these were in a preparation phase. Seventeen percent of these subjects said that they had not received advice on quitting smoking.There is a high rate of smoking in patients on LTDOT, with a higher probability of males and younger subjects continuing to smoke. There is a high level of physical dependency for nicotine.

Published
2010
Full Text
View/download PDF

7. Asociación de factores de riesgo cardiovascular y EPOC. Resultados de un estudio epidemiológico (estudio ARCE)

Author

Pilar de Lucas-Ramos, Jesús Molina-París, José Luis Izquierdo-Alonso, Eduardo Calvo-Corbella, Julio Ancochea-Bermúdez, José Miguel Rodríguez-González Moro, Myrian Calle-Rubio, Sonia Pons, José María Bellón-Cano, and Esteban Pérez-Rodríguez

Subjects
Pulmonary and Respiratory Medicine, Gynecology, medicine.medical_specialty, business.industry, Medicine, business
Abstract

Objetivo La enfermedad cardiovascular es una causa de muerte frecuente en los pacientes con enfermedad pulmonar obstructiva cronica (EPOC). No esta claro si el exceso de comorbilidad cardiovascular se relaciona con un incremento de factores de riesgo clasicos o si, por el contrario, la EPOC puede considerarse un factor de riesgo independiente. El objetivo de este estudio ha sido analizar la prevalencia de factores de riesgo y comorbilidad cardiovascular en una poblacion atendida en la comunidad por presentar EPOC. Pacientes y metodos Se ha realizado un estudio multicentrico, concurrente y transversal, en el que se incluyo a 572 pacientes con diagnostico confirmado de EPOC. Se recogieron datos de factores de riesgo y comorbilidad cardiovascular extraidos de la historia clinica del centro. Resultados El valor medio ± desviacion estandar del volumen espiratorio forzado en el primer segundo era del 53,7 ± 16,85% y la relacion volumen espiratorio forzado en el primer segundo/capacidad vital forzada del 57,9 ± 10,9%. La prevalencia de hipertension arterial era del 53%, la de obesidad del 27%, la de dislipemia del 26% y la de diabetes del 23%. La prevalencia de factores de riesgo no se relaciono con la gravedad de la enfermedad, pero si habia una tendencia de asociacion con la edad. La prevalencia de cardiopatia isquemica fue del 16,4%, la de enfermedad cerebrovascular del 7% y la de enfermedad vascular periferica del 17%. La prevalencia de comorbilidad vascular no se relaciono con la gravedad de la enfermedad, pero si con la edad y los factores de riesgo clasicos. Conclusiones Los pacientes con EPOC muestran una elevada prevalencia de factores de riesgo cardiovascular. La prevalencia de enfermedad cardiovascular y cerebrovascular excede la comunicada en poblacion general. No se ha observado relacion entre la gravedad de la obstruccion al flujo aereo y la presencia de comorbilidad cardiovascular.

Published
2008
Full Text
View/download PDF

8. Aging, Chronicity and Pulmonary Care

Author

Pilar de Lucas-Ramos and José Miguel Rodríguez González-Moro

Subjects
medicine.medical_specialty, National Health Programs, Pulmonary care, Delivery of Health Care, Integrated, business.industry, Disease Management, General Medicine, Respiration Disorders, Text mining, Pulmonary Medicine, medicine, Humans, Intensive care medicine, business
Published
2015
Full Text
View/download PDF

9. Prevalence and characteristics of three clinical phenotypes of chronic obstructive pulmonary disease (COPD)

Author

Esther Antón, Antonio Martín, José Luis Izquierdo-Alonso, José Miguel Rodríguez-González-Moro, Xabier Ribera, Irune Unzueta, and Pilar de Lucas-Ramos

Subjects
Pulmonary and Respiratory Medicine, Male, medicine.medical_specialty, Chronic bronchitis, Cross-sectional study, Comorbidity, Pulmonary function testing, Pulmonary Disease, Chronic Obstructive, Internal medicine, Forced Expiratory Volume, Activities of Daily Living, medicine, Prevalence, COPD, Humans, Bronchitis, Asthma, Aged, Clinical characteristics, business.industry, Sleep apnea, Cardiovascular Agents, Health Services, Middle Aged, medicine.disease, respiratory tract diseases, Pulmonology, Cross-Sectional Studies, Dyspnea, Phenotype, Pulmonary Emphysema, Spain, Chronic Disease, Physical therapy, Quality of Life, Female, business
Abstract

SummaryAimTo determine the prevalence and analyze the most relevant clinical characteristics of three clinical phenotypes of COPD: emphysema (type 1), chronic bronchitis (type 2) or COPD-asthma (type 3).MethodObservational, multicenter study performed with 331 COPD patients recruited in pulmonology outpatient services. The stratification in three phenotypes was performed with imaging tests, pulmonary function, and a standardized clinical questionnaire.ResultsThe 43.2% presented an emphysematous phenotype, 44.7% were chronic bronchitic and the other 12.1% presented a phenotype showing mixed characteristics with asthma. There were no significant differences in the smoking level, in the gasometric values or time of disease evolution. Type 1 patients showed lower FEV1 values in comparison with types 2 and 3, 46.6% (21.1), 55.2% (21.2) and 54.4% (21.8), respectively (p

Published
2012

10. Cardiovascular Biological Risk Markers In Patients With COPD

Author

Jose Mª Bellón Cano, Zoraida Verde Rello, José Miguel Rodríguez González-Moro, José Luis Izquierdo Alonso, Pilar de Lucas-Ramos, and Catalina Santiago Dorrego

Subjects
COPD, medicine.medical_specialty, business.industry, Internal medicine, medicine, In patient, medicine.disease, business
Published
2011
Full Text
View/download PDF

13. [Cardiovascular risk factors in chronic obstructive pulmonary disease: results of the ARCE study]

Author

José Miguel Rodríguez-González Moro, Jesús Molina-París, Pilar de Lucas-Ramos, Eduardo Calvo-Corbella, Myrian Calle-Rubio, Julio Ancochea-Bermúdez, José Luis Izquierdo-Alonso, José María Bellón-Cano, Sonia Pons, and Esteban Pérez-Rodríguez

Subjects
Adult, Male, Vital capacity, medicine.medical_specialty, Population, Hyperlipidemias, Disease, Comorbidity, Diabetes Complications, Pulmonary Disease, Chronic Obstructive, Risk Factors, Internal medicine, medicine, Prevalence, Humans, Risk factor, education, Aged, Demography, COPD, education.field_of_study, Framingham Risk Score, Vascular disease, business.industry, General Medicine, Middle Aged, medicine.disease, Cross-Sectional Studies, Cardiovascular Diseases, Physical therapy, Female, business
Abstract

Cardiovascular disease is a common cause of death in patients with chronic obstructive pulmonary disease (COPD). It is not clear whether the high cardiovascular comorbidity is due to an increase in traditional risk factors or whether, in contrast, COPD can be considered an independent risk factor. The aim of this study was to analyze the prevalence of risk factors and cardiovascular comorbidity in a community-based population treated for COPD.This was a concurrent multicenter, cross-sectional study that included 572 patients with confirmed diagnosis of COPD. Information on cardiovascular risk factors and comorbidity was collected by extracting data from the medical records of the participating center.The mean (SD) forced expiratory volume in 1 second (FEV1) was 53.7% (16.85%) of predicted and the ratio of FEV1 to forced vital capacity was 57.9% (10.9%). Hypertension was reported in 53%, obesity in 27%, dyslipidemia in 26%, and diabetes in 23% of the patients. The prevalence of risk factors was not related to disease severity, but there was a trend towards an association with age. In the study group, 16.4% had ischemic heart disease, 7% cerebrovascular disease, and 17% peripheral vascular disease. Cardiovascular disease was not associated with COPD severity, but such an association was reported for age and traditional risk factors.Cardiovascular risk factors are highly prevalent in patients with COPD. The prevalence of cardiovascular and cerebrovascular disease exceeds that reported in the general population. No relationship was found between the severity of airflow obstruction and the presence of cardiovascular comorbidity.

Published
2008

14. New GOLD classification: longitudinal data on group assignment

Author

Inmaculada Alfageme, Juan José Soler-Cataluña, Eva Balcells, Alfredo de Diego-Damia, Antonia Llunell, Nuria Feu-Collado, Ramón Agüero, Ingrid Solanes-García, Ciro Casanova, Borja G. Cosío, José Luis López-Campos, Rosa Irigaray, Pilar de Lucas-Ramos, Juan P. de-Torres, Cristina Martínez-González, Juan B. Galdiz, Joan B. Soriano, Miryam Calle-Rubio, Jose M. Marin, Isabel Mir-Viladrich, Margarita Marín, Germán Peces-Barba, and Universidad de Sevilla. Departamento de Medicina

Subjects
Pulmonary and Respiratory Medicine, BODE index, Spirometry, medicine.medical_specialty, Longitudinal data, humanos, Pulmonary disease, estudios de seguimiento, Cohort Studies, estudios prospectivos, Internal medicine, Humans, Medicine, COPD, Prospective Studies, Longitudinal Studies, GOLD, skin and connective tissue diseases, estudios de cohortes, mediana edad, Aged, anciano, medicine.diagnostic_test, business.industry, Research, Middle Aged, medicine.disease, Cohort, Physical therapy, Longitudinal, estudios longitudinales, Observational study, sense organs, business, Gold classification, Follow-Up Studies
Abstract

Rationale: Little is known about the longitudinal changes associated with using the 2013 update of the multidimensional GOLD strategy for chronic obstructive pulmonary disease (COPD). Objective: To determine the COPD patient distribution of the new GOLD proposal and evaluate how this classification changes over one year compared with the previous GOLD staging based on spirometry only. Methods: We analyzed data from the CHAIN study, a multicenter observational Spanish cohort of COPD patients who are monitored annually. Categories were defined according to the proposed GOLD: FEV1%, mMRC dyspnea, COPD Assessment Test (CAT), Clinical COPD Questionnaire (CCQ), and exacerbations-hospitalizations. One-year follow-up information was available for all variables except CCQ data. Results: At baseline, 828 stable COPD patients were evaluated. On the basis of mMRC dyspnea versus CAT, the patients were distributed as follows: 38.2% vs. 27.2% in group A, 17.6% vs. 28.3% in group B, 15.8% vs. 12.9% in group C, and 28.4% vs. 31.6% in group D. Information was available for 526 patients at one year: 64.2% of patients remained in the same group but groups C and D show different degrees of variability. The annual progression by group was mainly associated with one-year changes in CAT scores (RR, 1.138; 95% CI: 1.074-1.206) and BODE index values (RR, 2.012; 95% CI: 1.487-2.722). Conclusions: In the new GOLD grading classification, the type of tool used to determine the level of symptoms can substantially alter the group assignment. A change in category after one year was associated with longitudinal changes in the CAT and BODE index., AstraZeneca.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results